{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-119077","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.644008+00:00","generated_at":"2026-05-30T00:13:19.178580+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Marker Therapeutics reports Q3 2024 net loss of $2.3M; receives $4M NIH grants","bullets":["Cash and cash equivalents of $9.0M as of Sept 30, 2024; expects to fund operations into October 2025.","Net loss from continuing operations improved to $2.3M (Q3 2024) from $3.0M (Q3 2023).","R&D expenses rose to $3.5M (Q3 2024) vs $2.0M (Q3 2023) due to increased clinical trial activity.","Received two $2M SBIR grants from NIH ($4M total) to support MT-601 trials in lymphoma and pancreatic cancer.","Phase 1 APOLLO study of MT-601 in lymphoma continues enrolling; expects preliminary data by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-119077","json":"https://secwatch.observer/filing/0001104659-24-119077.json","markdown":"https://secwatch.observer/filing/0001104659-24-119077.md","text":"https://secwatch.observer/filing/0001104659-24-119077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924119077/0001104659-24-119077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924119077/tm2421372d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:13:19.178580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}